A Cleveland Clinic Phase 1 trial gave 15 patients with lipid disorders that had not responded well to drugs one infusion of CRISPR-Cas9 gene-editing therapy. After 12 months, those on the highest dose had a 52.5% drop in LDL cholesterol and a 47.8% fall in triglycerides from baseline, with no seriou